| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sunitinib | FIMM | pan-cancer | AAC | -0.19 | 0.3 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | 0.19 | 0.3 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | BHG712 | GDSC1000 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | -0.046 | 0.3 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.078 | 0.3 |